Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05075317
Other study ID # 21-5510
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 11, 2022
Est. completion date December 31, 2024

Study information

Verified date December 2023
Source University of Toronto
Contact Amy Kirkham, PhD
Phone ?(416) 946-4069?
Email amy.kirkham@utoronto.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will use a form of intermittent fasting called time-restricted eating (TRE) where individuals consume ad libitum energy intake within a set window of time, commonly 8 hours, which induces a fasting window of 16 hours per day (i.e., 16:8 TRE). TRE could be an effective addition to cardiac rehabilitation as it has demonstrated cardiovascular health benefits and potential for synergy when combined with exercise training. This study will determine if TRE is a feasible and safe nutrition intervention during cardiac rehabilitation and if TRE improves the health benefits of cardiac rehabilitation compared to cardiac rehabilitation alone.


Description:

HYPOTHESIS 1. Cardiac rehabilitation and TRE will be feasible in terms of adherence to a 16-hour daily fast (≥70%, which would represent 5/7 days/week) and safe (no excess symptoms or adverse events) 2. Cardiac rehabilitation and TRE will provide added cardiovascular health benefits (improved VO2peak, reduced fat mass) compared to cardiac rehabilitation alone. JUSTIFICATION: Past animal and human clinical trials have demonstrated TRE to be beneficial in realigning circadian rhythm, improve coronary artery disease (CAD) through the reduction in calorie intake, and promote cell signalling and repair pathways during the fasting period. TRE has not been tested in patients with CAD or other heart diseases but has shown to improve comorbid conditions (diabetes and hypertension) and improve metabolic profiles (blood pressure, hemoglobin A1c, fasting glucose, insulin sensitivity, and lipid profiles. Additionally, TRE when combined with exercise, such as in cardiac rehabilitation programs, improves VO2 peak and reduces fat mass compared to exercise alone. The proposed study will deliver a TRE intervention in combination with the cardiac rehabilitation program and is expected to be feasible, safe, and improve outcomes of cardiac rehabilitation. OBJECTIVES: The primary aim of this study is to evaluate the feasibility (adherence) and safety (adverse events) of TRE in combination with cardiac rehabilitation. The secondary aim is to assess the efficacy of the intervention on: 1. VO2peak, body composition, fasted glucose, hemoglobin A1c, blood pressure and waist circumference 2. Lifestyle behavioral change outcomes (dietary intake, dietary quality, physical activity, perceived stress) 4.Cardiac rehabilitation adherence Exploratory aims of the study include identifying sex differences (equal recruitment of males and females) and participants' experience with TRE (including confidence in maintaining this eating pattern or modifications to increase adherence). RESEARCH METHOD This study will be a two-site (Toronto Rehabilitation Institute and Toronto Western Hospital), 2-arm, parallel-group, randomized feasibility trial of cardiac rehabilitation alone or cardiac rehabilitation plus 16:8 TRE. Men and women who are referred through the standard clinical pathways for coronary artery disease and are willing to accept random assignment and complete the study assessments will be enrolled. Both groups will receive the standard, multi-dimensional cardiac rehabilitation program consisting of physician-directed risk factor management, an individualized exercise prescription, and virtual education. Participants randomized to the TRE group will be asked to eat only between 11 am and 7 pm for the duration of the cardiac rehabilitation program (~16 weeks). Adherence will be collected via twice daily text messages asking participants to respond with the time they started and stopped eating. Safety will be collected by self-report and medical records. Efficacy outcomes will be assessed by cardiopulmonary exercise test, blood draw, dual x-ray absorptiometry, 3-day diet records, accelerometers, and questionnaires. Study outcomes will be measured at baseline and at the end of the cardiac rehabilitation program. STATISTICAL ANALYSIS Participant characteristics will be summarized using descriptive statistics. For adherence, both the text message response rate and adherence rate to the 16-hour daily fast will be reported. The change in caloric intake, diet quality, physical activity and efficacy outcomes will be compared between groups by analysis of covariance with baseline values as covariates. Relative risk will be used to compare the incidence of safety outcomes between groups. The primary analysis will be intention to treat and performed with both sexes combined. Secondary analyses will be performed separately in each sex.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women who are referred and eligible for either the outpatient cardiac rehabilitation program for coronary artery disease - willing to accept random assignment and complete the study assessments - Equal numbers of men and women will be recruited Exclusion Criteria: - Inability to complete the consent form and communicate in English - Self-reported history of an eating disorder - Current or recent (1 year) pregnancy or breast feeding - Body mass index <18.5 kg/m^2 or clinical signs of cachexia - Contraindications or inability to perform cardiopulmonary exercise testing - Type 1 diabetes - Type 2 diabetes that requires exogenous insulin - Working night or rotating shifts - Eating window <12 hours or consistently eating less than 3 meals/day in the past 3 months

Study Design


Intervention

Behavioral:
Standard cardiac rehabilitation
Standard, multi-dimensional cardiac rehabilitation program.
Time-Restricted Eating
Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day

Locations

Country Name City State
Canada Toronto Rehabilitation Institute, University Health Network Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University of Toronto University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Macronutrient ratios 3-day food record analysed by food analysis software to estimate macronutrient intake 16 weeks
Other Caloric intake 3-day food record analysed by food analysis software to estimate intake 16 weeks
Other Cardiac rehabilitation adherence The participant's clinical chart for the cardiac rehabilitation program will be reviewed to extract adherence data to the standard components of the program (exercise, nutrition, education, social worker) 16 weeks
Other Time-restricted eating experience At the end of the intervention, the TRE group will complete a researcher developed questionnaire that asks questions about acceptability of TRE and confidence in continuing the intervention long-term 16 weeks
Other Mediterranean Diet Score Standard scoring of 14-item Mediterranean Diet Score Tool (minimum = 0, maximum = 14, higher score indicates better outcome) 16 weeks
Other Physical activity and sedentary time Participants will wear an accelerometer device for 5 days with 3 full days used for analysis 16 weeks
Primary Adherence to the daily =16-hour fast for the 16-weeks of the cardiac rehabilitation program. Assessed daily through a custom twice daily automated text message (or email) program, or written logs for those without cell phones. Adherence will be measured as a % of days with =16-hour fast. Averaged over the 16 weeks of the intervention
Primary Cardiorespiratory fitness as measured by peak volume of oxygen consumption (VO2peak) Assessed by an incremental, to-maximum cardiopulmonary treadmill exercise test. 16 weeks
Primary Fat mass Assessed by dual absorptiometry x-ray (DXA) scan. 16 weeks
Secondary Symptoms from TRE Self-report of various nutritional impact adverse events collected at support phone calls for both groups 16 weeks
Secondary Seattle Angina Questionnaire score Standard scoring of Seattle Angina Questionnaire (minimum = 0, maximum = 100, higher score means better outcome) 16 weeks
Secondary Adverse events re-hospitalizations, recurrent cardiac events, death extracted from medical records 1-year
Secondary Fat-free mass Assessed by dual absorptiometry x-ray (DXA) scan. 16 weeks
Secondary Hemoglobin A1c Measured by blood draw 16 weeks
Secondary Blood pressure Systolic and diastolic blood pressure will manually assessed as the average of the 2nd to 6th measurements 16 weeks
Secondary Waist circumference Measured by an inelastic tape at the level of the top of iliac crest as the average of two measurements 16 weeks
Secondary Fasted blood glucose Measured by fasted blood draw 16 weeks
Secondary Metabolic syndrome As defined by the NCEP/ATP III criteria 16 weeks
Secondary Lipid profile Individual measures and ratios of total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides from fasted blood draw 16 weeks
Secondary Health-related quality of life measured by the RAND-36 Physical Component Summary Physical component summary of the RAND-36 questionnaire (minimum = 0, maximum = 50, higher score is better outcome) 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A